AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$CSTL

Juvenal Tobin W sold $223K of CSTL

Juvenal Tobin W (Chief Commercial Officer) sold 6,600 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $33.73 ($32.32–$35.14, $0.22M total) across 2 trades over 2026-09-14 to 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Juvenal Tobin W
Published Sep 16, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Neutral
high confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

The transaction is a standard 10b5-1 sale with modest value, offering limited trading insight.

02

Market read

Low relevance; insider sale size is small and unlikely to affect market perception.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Sep 16, 2026 after market close

Background

Form 4 filing by Castle Biosciences' CCO, a routine disclosure of insider transactions.

Company-level read

Ticker impact

$CSTLNeutralHigh confidence
Context

Chief Commercial Officer sold 6,600 shares for $222.6K via 10b5-1 plan, reducing holdings to 58,584 shares.

Expected impact

No significant impact; price likely unchanged.

Evidence & confidence

Sale size is small relative to market cap and disclosed via routine 10b5-1 plan.

Market effects

Sector

None; insider sale does not affect biotech sector broadly.

Regional

No regional impact.

Global

Limited to Castle Biosciences shareholders.

Counterpoint

What could challenge this read

Sale could signal insider confidence in future growth despite reduction.

Key entities

  • Company
    Castle Biosciences Inc

    Biotech firm listed on Nasdaq (CSTL).

  • Insider
    Juvenal Tobin W

    Chief Commercial Officer of Castle Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min